AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11732382
Drug: tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tenoxicam 40 mg intramuscularly (i.m.)
Trial: 11732382
Drug: piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piroxicam 40 mg intramuscularly (i.m.)
Trial: 9218667
Drug: Stepped‐care antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped‐care antihypertensive drug therapy (chlorthalidone 12.5-25 mg or matching placebo, atenolol 25-50 mg or matching placebo)
Trial: 9218667
Drug: Stepped‐care antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped‐care antihypertensive drug therapy (for patients with prior MI)
Trial: 7970063
Drug: Thymopentin-TP5 in
RxNorm normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin-TP5 in addition to antibiotic prophylaxis
Trial: 2885462
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy alone
Trial: 3121487
Drug: DOM (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOM (5 mg/h infusion)
Trial: 3121487
Drug: GHRH (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (50 micrograms i.v.) plus DOM (5 mg/h i.v.)
Trial: 29974278
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (OK + atropine 0.01% ophthalmic solution)
Trial: 27001471
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group (tablet containing 20 mg of lactoferrin, 2.6 mg of lactoperoxidase, and 2.6 mg of glucose oxidase)
Trial: 24793963
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo tablet)
Trial: 23876539
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol plus perivascular vasopressin
Trial: 18851773
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT)
Trial: 16556541
Drug: Three near
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three near zero-order controlled-release pseudoephedrine hydrochloride formulations
Trial: 16556541
Drug: Three formulations
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three formulations
Trial: 1976875
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin
Trial: 25583364
Drug: Sertindole (12-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole (12-20 mg)
Trial: 14503664
Drug: Intranasal doses
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal doses of IS-159 (1, 2, 4, and 6 mg) administered twice at an interval of 4 hours
Trial: 6418181
Drug: Slow-release capsule
RxNorm normalized name: Bontril 105mg Slow-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release capsule of ketoprofen lysine (160 mg)
Trial: 6418181
Drug: Conventional capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional capsules of ketoprofen lysine (Artrosilene®) (160 mg)
Trial: 31081485
Drug: ParkinSong intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ParkinSong intervention (weekly dosage)
Trial: 31081485
Drug: ParkinSong intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ParkinSong intervention (monthly dosage)
Trial: 30139035
Drug: Hydromorphone supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone supplement with dexmedetomidine 1 μg/kg group (D1 group)
Trial: 25954844
Drug: Oral A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral A. montana (Alpine Pharmaceuticals)
Trial: 21808284
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray nicotine replacement therapy
Trial: 20949341
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules taken intact with water under fasting conditions
Trial: 20949341
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules sprinkled on apple sauce
Trial: 20949341
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules under all treatment conditions
Trial: 17619791
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS), beclomethasone dipropionate 250 microg/day
Trial: 15895834
Drug: Experimental injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental injection of 0.5 mL of hypertonic (6%) saline
Trial: 15895834
Drug: Control injection
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injection of 0.5 mL isotonic (0.9%) saline
Trial: 17678570
Drug: Soya-based capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya-based capsules (35 mg isoflavones equivalent aglycone)
Trial: 17678570
Drug: Soya-based cheese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya-based cheese (35 mg isoflavones equivalent aglycone)
Trial: 10553821
Drug: Nicardipine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 0.25 mg IV bolus
Trial: 10553821
Drug: Nicardipine 2.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 2.00 mg IV bolus
Trial: 6182412
Drug: Nicardipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (all doses)
Trial: 29855695
Drug: Chemoimmunotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (group A, immunotherapy arm)
Trial: 29855695
Drug: Chemotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (group B, control arm)
Trial: 20860888
Drug: Antidepressants (SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (SSRIs prescribed by GP)
Trial: 17473917
Drug: Atacicept (2.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (2.1, 70, 210 or 630 mg)
Trial: 17473917
Drug: Atacicept (70,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (70, 210, 630 mg)
Trial: 350346
Drug: Bromhexine 24
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 24 mg/day
Trial: 350346
Drug: Bromhexine 48
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 48 mg/day
Trial: 25854012
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) applied to Sanyinjiao (SP 6), Zigong (EX CA 1), Zhongji (CV 3), and Guanyuan (CV 4), treatment given once every two days until egg collection, needles retained for 30 min each time
Trial: 28161352
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg (escalated to 10 mg at week 6)
Trial: 16698413
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment every 2 months for 12 months (total of 7 treatments)
Trial: 3398127
Drug: Postoperative course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative course of oral antibiotics (group 2)
Trial: 3398127
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (controls, group 1)
Trial: 20529983
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg hyperbaric 2% prilocaine
Trial: 20529983
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg hyperbaric 2% prilocaine
Trial: 16603098
Drug: Clotrimazole (antimycotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (antimycotic agent)
Trial: 9520227
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg q.i.d.) plus Codeine (40 mg q.i.d.)
Trial: 9520227
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg q.i.d.) plus Imipramine (10 or 25 mg t.i.d.)
Trial: 2622580
Drug: Ofloxacin 600
RxNorm normalized name: ofloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 600 mg/day for 3 days
Trial: 2622580
Drug: Ofloxacin 300
RxNorm normalized name: ofloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 300 mg/day for 3 days
Trial: 2622580
Drug: Ofloxacin 600
RxNorm normalized name: ofloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 600 mg/day for 5 days
Trial: 1091029
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of adenine infused intravenously over one hour
Trial: 1091029
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of adenine infused intravenously over one hour
Trial: 28606267
Drug: Lipid‐containing carbomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid‐containing carbomer gel (Group C)
Trial: 28606267
Drug: Conventional antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antibiotics (Group A)
Trial: 17432638
Drug: Eye-needling combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye-needling combined with medication
Trial: 10069757
Drug: Subcutaneous low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low-molecular-weight heparin (LMWH), tinzaparin sodium, once-daily dose.
Trial: 7992418
Drug: Incision, curettage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision, curettage and primary suture under antibiotic cover
Trial: 7992418
Drug: Conventional, 'open'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional, 'open' treatment
Trial: 1969068
Drug: Conventional perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional perioperative antibiotic prophylaxis (controls)
Trial: 21543951
Drug: Dual-focus schema
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-focus schema therapy
Trial: 25799306
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling
Trial: 19483514
Drug: 11-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-valent pneumococcal conjugate vaccine (11PCV)
Trial: 10361108
Drug: TAD-HAM (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAD-HAM (high-dose cytarabine with mitoxantrone)
Trial: 10361108
Drug: TAD (standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAD (standard-dose cytarabine with daunorubicin and 6-thioguanine)
Trial: 2155476
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid, carprofen, diclofenac, indomethacin, naproxen, proquazone, timegadine, tolfenamic acid, paracetamol
Trial: 31719078
Drug: Nasogastric (NG)
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasogastric (NG) route - 8 infusions over 4 days, then again for 4 days in week 4 (total of 240 g of stool)
Trial: 31719078
Drug: Colonoscopic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colonoscopic infusion followed by seven weekly enemas (total of 360 g of stool)
Trial: 26209856
Drug: Single intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraoperative dose of dexamethasone
Trial: 22132755
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks.
Trial: 20084933
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment
Trial: 17087245
Drug: Clexane, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clexane, 40 mg, administered 12 hours before and within 7-18 days after surgery
Trial: 15021224
Drug: High-risk OH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk OH and Primary Open Angle Glaucoma (POAG) treatment
Trial: 9286520
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum containing 0.25 mg F as NaF for 5, 10, 15, 20, 30, or 45 minutes
Trial: 12959292
Drug: Modified metered‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified metered‐dose actuator device (MA)
Trial: 12959292
Drug: Standard metered‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard metered‐dose inhaler (MDI)
Trial: 31096498
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate solution 710 mL the night before and 355 mL 2 hours prior to operation
Trial: 23032410
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with ritonavir-boosted lopinavir (LPV/r)
Trial: 23032410
Drug: Continued therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued therapy
Trial: 16957558
Drug: Methionine 100
RxNorm normalized name: methionine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine 100 mg/kg (study 1)
Trial: 16957558
Drug: Methionine 200
RxNorm normalized name: methionine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine 200 mg/kg (study 2)
Trial: 15354036
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (20% in saline; carbohydrate (CHO) at a rate of 1 g x min(‐1))
Trial: 7978956
Drug: Gonadotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin‐releasing hormone agonist (GnRHa) in depot formulation (Zoladex) with transdermal 17‐beta‐estradiol and oral progestin
Trial: 31702802
Drug: Bimodal release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimodal release ondansetron (6 mg immediate release and 18 mg 24-hour release, total 24 mg)
Trial: 28229892
Drug: Opicinumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicinumab (100 mg/kg intravenously once every 4 weeks for six doses)
Trial: 28229892
Drug: Placebo (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenously once every 4 weeks for six doses)
Trial: 23116775
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (ferrous sulfate, 10 mg of elemental iron per day)
Trial: 21349218
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg) + Mebendazole (500 mg)
Trial: 21349218
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg) alone
Trial: 19346844
Drug: Intravenous beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous beta-blocker (landiolol hydrochloride, mean dose of 0.032 mg/kg per minute)
Trial: 19346844
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of intravenous beta-blocker and sublingual NTG (0.3 mg)
Trial: 11304056
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg/kg over 48 hours)
Trial: 11304056
Drug: Halofantrine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (8 mg/kg, 3 doses)
Trial: 1505554
Drug: Reference, hospital-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference, hospital-based treatment (H) group
Trial: 28772281
Drug: Linsitinib 150
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linsitinib 150 mg BID plus erlotinib 150 mg QD
Trial: 28772281
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus erlotinib 150 mg QD
Trial: 26964164
Drug: Acupoint application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint application therapy with bushentongyu plaster and tamsulosin hydrochloride (0.2 mg every night for 100 days)
Trial: 26964164
Drug: Tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin hydrochloride (0.2 mg every night for 100 days)
Trial: 23767986
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily oral rasagiline (monotherapy)
Trial: 23767986
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily oral rasagiline (adjunct therapy with levodopa)
Trial: 23767986
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily oral rasagiline (adjunct therapy)
Trial: 21285525
Drug: Self-stretching and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-stretching and soft tissue TrP manual therapy (Str-ST)
Trial: 3913728
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and Control
Trial: 3304625
Drug: Intensive course
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive course of chemotherapy consisting of vincristine, procarbazine and methotrexate, followed by citrovorum factor rescue
Trial: 29022212
Drug: Saroglitazar magnesium
RxNorm normalized name: Magnesium
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar magnesium 4-mg tablet under fed conditions (high-calorie and high-fat breakfast)
Trial: 29022212
Drug: Saroglitazar magnesium
RxNorm normalized name: Magnesium
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar magnesium 4-mg tablet under fasting conditions
Trial: 23672318
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (0.25 mg/kg bupivacaine 0.5%)
Trial: 28120485
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg
Trial: 6130076
Drug: Buspirone 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 40 mg
Trial: 7519702
Drug: Buspirone 5
RxNorm normalized name: busPIRone 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 5 mg
Trial: 28120485
Drug: Buspirone 10
RxNorm normalized name: busPIRone 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 10 mg
Trial: 10943585
Drug: Thrombolytic agent
RxNorm normalized name: Thrombolytic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agent (urokinase or streptokinase), n = 12
Trial: 10943585
Drug: Heparin, n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin, n = 11
Trial: 8765432
Drug: UFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT plus leucovorin (30 mg/day)
Trial: 8765432
Drug: UFT alone
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT alone (400 mg/day)
Trial: 2013559
Drug: Ketotifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen treatment
Trial: 6148878
Drug: Nadolol 80
RxNorm normalized name: nadolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 80 mg/day
Trial: 1124717
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg/day
Trial: 30876431
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS (current stimulation for 30 s) combined with upper limb physical therapy (20 min passive movement + 20 min active mini-bike) for 10 sessions.
Trial: 30876431
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (2 mA) combined with upper limb physical therapy.
Trial: 20927781
Drug: GDC-0449 (hedgehog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0449 (hedgehog pathway inhibitor), once per day continuous therapy, oral administration
Trial: 9542555
Drug: Propacetamol +
RxNorm normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol + PCA morphine
Trial: 30648919
Drug: PCV15 Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV15 Formulation A
Trial: 26054135
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion treatment applied to specific acupuncture points (Shenque, Zhongji, Guanyuan, Qihai, Zigong, Xuebai) for 3 sessions until transfer time.